Jose Ricardo Soares: Genomic Testing for All Patients Considered for Clopidogrel in UK
Jose Ricardo Soares, Relief Pharmacist at Uniphar Group, reposted from University of Liverpool on LinkedIn:
”Genomic testing for all patients considered for clopidogrel (before therapy starts). UK.
Clopidogrel empirically prescribed by doctors is not working in a staggering 29% of patients – being in those ineffective in prevention of stroke or MI.
Why: being a prodrug it must be activated via CYP 2C19 — patients with loss‑of‑function these CYP variants (intermediate/poor metabolisers) get much less antiplatelet effect and more thrombotic events.
So: the UK Centre of Excellence in Regulatory Science and Innovation in Pharmacogenomics issued a guideline that recommends CYP2C19 genotyping for all patients in whom clopidogrel is being considered, “where testing is available”.
My opinion, this means that testing will soonly be available in secondary care units across the UK.
Moreover: the PGx (pharmacogenomics) data is stored as structured data into the shared electronic health record, information readily available to the prescribers (hospital, GP/community systems).
This way it will be a once in a lifetime test.
Looks quite futuristic for a patent-expired medicine.”
Quoting University of Liverpool‘s post:
”NEWS I: New UK guideline for clopidogrel recommends pharmacogenetic testing for all patients before prescription
The UK Centre of Excellence in Regulatory Science and Innovation in Pharmacogenomics, led by the University of Liverpool, has published its first clinical guideline focused on the use of the antiplatelet medication clopidogrel, widely prescribed in the UK to prevent blood clots. Pharmacogenomics looks at how differences in our genes can change the way medicines affect each person.
Find out more here.”
Read the full article here.
Stay updated with Hemostasis Today.
-
May 14, 2026, 16:46Michele Romoli: Neurointerventional Workforce Gaps and Stroke Thrombectomy Access in Europe
-
May 14, 2026, 16:34Julia Owens: Improving Acute Stroke Care for Patients Without Timely Intervention
-
May 14, 2026, 16:28Krish Patel։ Opioid Overdose and Heart-Related Deaths in the USA (1999–2023)
-
May 14, 2026, 16:26Carla Goulart Peron: 79th World Health Assembly Momentum for Global Stroke Action
-
May 14, 2026, 16:21Love Preet Kalra: Honored to Present Our Data on Plasma GFAP Measurements for ICH at ESOC 2026
-
May 14, 2026, 16:09Dino Mehic: BDUC and Its Overlap With Inherited and Rare Bleeding Disorders
-
May 14, 2026, 16:06Silvia Escribano Serrat: Flow Cytometric Osmotic Fragility Testing for Diagnosis of Hereditary Spherocytosis
-
May 14, 2026, 16:01Harlinde Peperstraete: From Circuit to Coagulation – Understanding Hemostasis in ECMO
-
May 14, 2026, 15:47Nathan Connell: A Valuable and Timely Discussion on The Future of Global Health Equity